Avidity Biosciences, Inc. RNA
Institutional shares held
139 Million
1.24M
calls
531K
puts
Total value of holdings
$9.85B
$87.8M
calls
$37.6M
puts
Market Cap
$3.69B
52,127,000
Shares Out.
Institutional ownership
267.03%
# of Institutions
311
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Janus Henderson Group PLC London, X014.5MShares$1.03 Billion0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$936 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY11.4MShares$805 Million6.62% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$713 Million0.08% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.79MShares$693 Million0.05% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.64MShares$612 Million6.47% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$610 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.65MShares$541 Million4.55% of portfolio
-
State Street Corp Boston, MA4.89MShares$346 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.86MShares$202 Million0.01% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 22
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,209
-5.38%
|
$103,823
$47.54 P/Share
|
|
Oct 22
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,209
+5.1%
|
$22,090
$10.16 P/Share
|
|
Oct 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
20,000
-17.08%
|
$1,000,000
$50.15 P/Share
|
|
Oct 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+14.58%
|
$440,000
$22.34 P/Share
|
|
Oct 03
2025
|
Eric Mosbrooker Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,562
-10.66%
|
$295,290
$45.38 P/Share
|
|
Oct 03
2025
|
Eric Mosbrooker Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,562
+9.63%
|
$59,058
$9.05 P/Share
|
|
Sep 22
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,208
-5.38%
|
$88,320
$40.58 P/Share
|
|
Sep 22
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,208
+5.1%
|
$22,080
$10.16 P/Share
|
|
Sep 15
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,542
-3.82%
|
$69,390
$45.41 P/Share
|
|
Sep 15
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,542
+3.68%
|
$9,252
$6.57 P/Share
|
|
Sep 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
15,000
-13.38%
|
$615,000
$41.41 P/Share
|
|
Sep 15
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+11.8%
|
$330,000
$22.34 P/Share
|
|
Sep 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-19.96%
|
$760,000
$38.94 P/Share
|
|
Sep 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.64%
|
$280,000
$14.22 P/Share
|
|
Sep 05
2025
|
Troy Edward Wilson Director |
SELL
Open market or private sale
|
Direct |
29,500
-19.44%
|
$1,475,000
$50.0 P/Share
|
|
Sep 05
2025
|
Troy Edward Wilson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,500
+14.73%
|
$174,000
$12.48 P/Share
|
|
Sep 05
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-14.05%
|
$2,450,000
$49.95 P/Share
|
|
Sep 05
2025
|
Sarah Boyce President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+12.32%
|
$50,000
$1.24 P/Share
|
|
Sep 03
2025
|
Eric Mosbrooker Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,563
-10.66%
|
$308,461
$47.07 P/Share
|
|
Sep 03
2025
|
Eric Mosbrooker Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,563
+9.63%
|
$59,067
$9.05 P/Share
|
Last 12 Months Summary
Buy / Acquisition
984K
Shares
From
25
Insiders
| Grant, award, or other acquisition | 351K shares |
|---|---|
| Exercise of conversion of derivative security | 633K shares |
Sell / Disposition
961K
Shares
From
10
Insiders
| Open market or private sale | 961K shares |
|---|